Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study

It is not known if new onset diabetes during Coronavirus-19 disease (COVID-19; NOD COVID) is phenotypically or biochemically different than new onset diabetes before COVID-19 (NOD). All adults diagnosed with new onset diabetes from during the time of COVID-19 were compared with new onset diabetes pr...

Full description

Saved in:

Bibliographic Details
Published in:	Diabetes & metabolic syndrome clinical research & reviews Vol. 15; no. 1; pp. 215 - 220
Main Authors:	Ghosh, Amerta, Anjana, Ranjit Mohan, Shanthi Rani, Coimbatore Subramanian, Jeba Rani, Saravanan, Gupta, Ritesh, Jha, Alka, Gupta, Vimal, Kuchay, Mohammad Shafi, Luthra, Atul, Durrani, Suhail, Dutta, Koel, Tyagi, Kanika, Unnikrishnan, Ranjit, Srivastava, Brijendra Kumar, Ramu, Muthu, Sastry, Nadiminty Ganapathi, Gupta, Prasanna Kumar, Umasankari, Ganesan, Jayashri, Ramamoorthy, Mohan, Viswanathan, Misra, Anoop
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 01-01-2021 Diabetes India. Published by Elsevier Ltd
Subjects:	Adult Blood Glucose - metabolism COVID-19 COVID-19 - blood COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 antibody Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - epidemiology Female Glycemic Index - physiology Humans India - epidemiology Male Middle Aged New-onset diabetes Pandemics Tertiary Care Centers - trends Type 2 diabetes India COVID-19 Type 2 diabetes Diabetes COVID-19 antibody New-onset diabetes
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	It is not known if new onset diabetes during Coronavirus-19 disease (COVID-19; NOD COVID) is phenotypically or biochemically different than new onset diabetes before COVID-19 (NOD). All adults diagnosed with new onset diabetes from during the time of COVID-19 were compared with new onset diabetes prior to COVID-19 from two tertiary care hospitals in Chennai and Delhi. RTPCR test for SARS-CoV-2 virus was done as appropriate, and COVID-19 antibody test was done in all other NOD COVID patients. A total of 555 patients with new onset diabetes were included in the study (282 NOD and 273 NOD COVID patients). Patients with NOD COVID had higher fasting and post prandial blood glucose and glycated hemoglobin levels vs. NOD patients. Both the groups had high average body mass index; ∼28 kg/m2. Interestingly, fasting C-peptide levels were significantly higher in the NOD COVID group vs. NOD group. There was no difference in C-peptide levels or glycemic parameters between the COVID-19 antibody positive and negative NOD COVID cases. Individuals who were diagnosed with diabetes during COVID-19 epidemic (NOD COVID) do not significantly differ from those diagnosed before COVID-19 in symptomatology, phenotype, and C-peptide levels but they had more severe glycemia. •We studied 282 patients with new-onset diabetes before COVID-19 (NOD), and 273 new onset patients with diabetes during COVID-19 (NOD COVID).•Patients with NOD COVID had higher fasting and post prandial blood glucose and glycated hemoglobin vs. to NOD patients.•There was no difference in C-peptide or glycemic parameters between the COVID-19 antibody positive and negative NOD COVID cases.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Joint corresponding authors. Joint first authors.
ISSN:	1871-4021 1878-0334
DOI:	10.1016/j.dsx.2020.12.033